President and CEO,
Pharmaceutical Research and Manufacturers of America
Ubl and the pharmaceutical industry have been successful in derailing legislative efforts in Congress to curtail drug prices. The industry also fought a Trump administration rule that would have forced drugmakers to post their list prices in television ads. In October, Ubl said if the drug price bill passes Congress, small start-up biopharmaceutical firms that depend on venture capital will vanish.